19218-88-3

Upstream product

• 71-41-0 pentan-1-ol 
• 50-84-0 2,4 dichlorobenzoic acid 
• 62-53-3 aniline 
• 13421-13-1 4-chloro-2-iodobenzoic acid 
• 936-08-3 2-bromo-4-chlorobenzoic acid 
• 32606-06-7 (3,7-dichloro-2,4-dioxo-1-phenyl-1,2,3,4-tetrahydro-quinolin-3-yl)-acetic acid 

Downstream Products

• 61573-15-7 7-chloro-1-phenyl-1H-benzo[d][1,3]oxazine-2,4-dione 
• 5509-37-5 4-Chlor-N-phenylanthranilsaeuremethylester 
• 195370-32-2 C₁₄H₁₃ClN₄OS 
• 409111-71-3 2-[N-(2-anilino-4-chloro-benzoyl)-anilino]-4-chloro-benzoic acid 
• 409111-73-5 2-anilino-4-chloro-benzoic acid-anhydride 
• 16075-19-7 7-chloro-1-phenyl-1,2-dihydro-benzo[d][1,3]thiazin-4-one 
• 1402345-30-5 4-chloro-N-methoxy-N-methyl-2-phenylamino-benzamide 
• 31376-66-6 C₁₅H₁₄ClNO₂ 
• 270088-53-4 3-Chloro-9-(4-nitro-phenylsulfanyl)-acridine 
• 6269-27-8 3-chloroacridin-9(10H)-one 
• 23310-35-2 (E)-6,6'-dichloro-1,1'-diphenyl-1H,1'H-[3,3']bi[benzo[c]isothiazolylidene] 
• 16095-45-7 7-chloro-1-phenyl-1,2-dihydro-benzo[d][1,3]oxazin-4-one 
• 35547-70-7 3,9-dichloroacridine 
• 58658-41-6 3-chloro-10-methylacridin-9(10H)-one 

Relevant academic research and scientific papers

Sp2CH?Cl hydrogen bond in the conformational polymorphism of 4-chloro-phenylanthranilic acid

Chlorine can participate in numerous interactions such as halogen bonding, hydrogen bonding, and London dispersion in the solid state. In this work, we report the influence of a chlorine substituent on the polymorphism of a potential anticancer drug, 4-ch

2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS

Disclosed herein are certain 2-oxoquinazoline derivatives of Formula (IA): (IA) that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.

Redox-neutral decarboxylative photocyclization of anthranilic acids

A mild metal-, catalyst-, and oxidant-free photoredox neutral system has been found to efficiently enable intramolecular decarboxylative cyclization of anthranilic acids. This facile protocol provides an alternative method for the synthesis of carbazoles. Mechanistic studies reveal a key photoinduced 6π-electrocyclization process and formic acid was released as the sole byproduct.

Light-Driven Intramolecular C?N Cross-Coupling via a Long-Lived Photoactive Photoisomer Complex

Reported herein is a visible-light-driven intramolecular C?N cross-coupling reaction under mild reaction conditions (metal- and photocatalyst-free, at room temperature) via a long-lived photoactive photoisomer complex. This strategy was used to rapidly prepare the N-substituted polycyclic quinazolinone derivatives with a broad substrate scope (>50 examples) and further exploited to synthesize the natural products tryptanthrin, rutaecarpine, and their analogues. The success of gram-scale synthesis and solar-driven transformation, as well as promising tumor-suppressing biological activity, proves the potential of this strategy for practical applications. Mechanistic investigations, including control experiments, DFT calculations, UV-vis spectroscopy, EPR, and X-ray single-crystal structure of the key intermediate, provides insight into the mechanism.

A rapid, chromatography-free route to substituted acridine-isoalloxazine conjugates under microwave irradiation

Microwave irradiation was applied to a sequence of condensation reactions from readily available 9-chloroacridines to provide a range of novel acridine-isoalloxazine conjugates. The combination of these two moieties, both of biological interest, was achieved by a chromatography-free route.

PhI(OAc)2-mediated intramolecular oxidative aryl-aldehyde C sp 2-C sp 2 bond formation: Metal-free synthesis of acridone derivatives

A metal-free protocol for direct aryl-aldehyde Csp2-Csp 2 bond formation via a PhI(OAc)2-mediated intramolecular cross-dehydrogenative coupling (CDC) of various 2-(N-arylamino)aldehydes was developed. The novel methodology requires no need of preactivation of the aldehyde group, is applicable to a large variety of functionalized substrates, and most of all provides a convenient approach to the construction of biologically important acridone derivatives.

Novel synthetic acridine derivatives as potent DNA-binding and apoptosis-inducing antitumor agents

Acridine derivatives have been explored as DNA-binding anticancer agents. Some derivatives show undesired pharmacokinetic properties and new derivatives need to be explored. In this work, a series of novel acridine analogues were synthesized by modifying previously unexplored linkers between the acridine and benzene groups and their antiproliferative activity and the DNA-binding ability were evaluated. Among these derivatives, compound 5c demonstrated DNA-binding capability and topoisomerase I inhibitory activity. In K562 cell lines, 5c induced apoptosis through mitochondria-dependent intrinsic pathways. These data suggested that compound 5c and other acridine derivatives with modified linkers between the acridine and benzene groups might be potent DNA-binding agents.

Sc(OTf)3-catalyzed dehydrogenative cyclization for synthesis of N-methylacridones

A novel method has been developed for the synthesis of substituted N-methylacridones from 2-(N-methyl-N-phenylamino)benzaldehydes via dehydrogenative cyclization. This transformation involves two primary processes: the aldehyde first coordinates with Sc(OTf)3 and induces the aromatic electrophilic substitution (SEAr) reaction to form the active intermediate N-methyl-acridin-9-ol, which is then quickly oxidized in situ to afford the acridones. Furthermore, the procedure involved is both environmental friendly and atom efficient; H2O is the only byproduct in this reaction.

AMINOMETHYL QUINOLONE COMPOUNDS

The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula (I): wherein the variables ar

ADAMANTYL COMPOUNDS

The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula I: wherein the variables are